A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

A*STAR researchers have developed a point-of-care rapid antibody test kit that can detect antibodies produced in response to SARS-CoV-2 infection in just fifteen minutes.

Researchers at A*STAR have discovered how a class of small proteins is essential for metabolism.

Using magnets, scientists have developed an innovative pressure-based technique that represents a new frontier in needle-free drug delivery.

An international consortium gives a debilitating childhood disorder a name and a genetic cause.

In the search for new therapeutics and diagnostic tools, Sherry Aw is unraveling the biology behind movement disorders using the humble fruit fly.

A study implicates novel genetic risk factors in a rare and aggressive lymphoma affecting Asian populations.

Clinicians and scientists have discovered a rare mutation that impairs the immune system, and are using their findings to devise treatment strategies

Antibodies that recognize the SARS-CoV-2 spike protein show potential for diagnosing COVID-19.

The presence of memory T cells in COVID-19-recovered patients hints at their importance in COVID-19 immunity.

A*STAR researchers have developed a biodegradable polymeric drug carrier that can target cancerous tissue in the lungs and liver.

Antiviral strategies against COVID-19 broadly fall into two groups: those that target the virus and those that target the host factors that are essential for virus replication.

Tipped off by artificial intelligence, a research team is testing whether a rheumatoid arthritis drug could be repurposed as a COVID-19 treatment.